10-Q · October 28, 2025
Ekso Bionics Holdings, Inc. reported a slight increase in revenue of 2% to $4.227 million for Q3 2025 compared to Q3 2024. The company achieved a significant reduction in net loss, down 31% year-over-year, while gross…
Earnings analysis · 10-K
CHRN earnings analysis
Filed February 23, 2026 · Our reading of the company's report
The latest report
Ekso Bionics Holdings, Inc. provides cutting-edge exoskeleton and complementary products for healthcare and personal use, targeting individuals with physical disabilities. The company reported a significant revenue…
Read full summary
Ekso Bionics Holdings, Inc. provides cutting-edge exoskeleton and complementary products for healthcare and personal use, targeting individuals with physical disabilities. The company reported a significant revenue decrease of 29% for 2025, attributed primarily to decreased sales in the Enterprise Health market, while initiating new sales avenues in Personal Health following Medicare reimbursements for the Ekso Indego Personal device. Financial constraints and upcoming business combinations signal challenges ahead.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-4.91
- Gross margin
- 53%
- Segment
- Enterprise Health
- Segment
- Personal Health
What stood out
-
Product Roadmap Expansion
Plans to market the MediTouch BalanceTutor starting early 2026, expected to complement existing exoskeleton products.
-
Medicare Approval Boosts Sales Potential
Medicare approved the Ekso Indego Personal for $91,000 reimbursement, potentially increasing demand among estimated 309,000 SCI patients in the U.S.
-
Increased Focus on Personal Health Market
Witnessed increased claims and reimbursements in the Personal Health market, expected greater year-over-year contribution in 2026.
-
Partnerships with Leading DMEs Established
Signed agreements with National Seating & Mobility, Bionic Prosthetics & Orthotics Group, and Ottobock to enhance go-to-market strategies.
-
Reduction in Operating Expenses
Operating expenses were stable despite a drop in revenue, indicating cost control efforts.
-
Successful Completion of Preferred Stock Placement
Completed a Private Placement generating approximately $5.3 million for working capital needs.
What to watch
-
Revenue Decline Threats
Revenue fell by $5.1 million (29%) from 2024 to 2025 primarily due to decreased Enterprise Health device sales.
-
Financial Stability Concerns
As of December 31, 2025, the company had a cash balance of only $1.2 million and substantial operational losses, raising doubts about liquidity.
-
Rising Competition Impact
Increasing competition in healthcare technology, especially due to price-based pressures, negatively impacting sales, particularly in EMEA.
Management's outlook
Revenue is expected to primarily derive from Enterprise Health but with Personal Health sales gradually contributing more. Detailed annual guidance to be discussed in earnings call.
Earlier filings 2
10-Q · July 28, 2025
Ekso Bionics Holdings, Inc. reported a significant decline in revenue of 58% to $2.06 million for Q2 2025 compared to Q2 2024, largely due to delays in Enterprise Health device sales transitioning to Personal Health…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.